Longboard Pharmaceuticals, Inc.

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In the top alliance by deal value, Monte Rosa Therapeutics granted Novartis exclusive global rights to develop, manufacture and commercialize Phase I MRT-6160 for immune-mediated conditions as well as